abstract |
Patients who are susceptible to, or suffer from conditions and disorders, such as disorders of the central nervous system, are treated by administering to a patient requiring aryloxyalkylamines, including pyridyloxyalkylamines and phenoxyalkylamines, such as (3- (3-pyridyloxy) propyl ) methylamine and (3- (5-bromo (3- pyridyloxy)) propyl) methylamine. |